Drug Trial News

RSS

Nature News examines controversy surrounding Indian HPV vaccine trial

After four teenage girls involved in a clinical trial in India testing vaccines for human papillomavirus (HPV) died last year, the study "threatens to have a dual legacy: inflaming unfounded fears about a lifesaving vaccine and raising new questions about the management of medical research in the country," Nature News reports.

24 Jun 2011

Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma

Millennium: The Takeda Oncology Company today announced the presentation of results from an ongoing Phase II study of MLN8237, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory aggressive B-cell and T-cell non-Hodgkin lymphoma.

24 Jun 2011

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.

24 Jun 2011

Oxytocin hormone holds promise for children with Prader-Willi syndrome

Prader-Willi syndrome is a rare genetic disorder which affects one child in 25,000. Children born with this syndrome have a range of complex neurological and developmental problems which continue into adult life. These can manifest as cognitive and behavioral difficulties, weight gain, problems in controlling their temper and attendant difficulties in socialization.

24 Jun 2011

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

24 Jun 2011

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a third site for testing the therapeutic potential of its HIV/AIDS vaccine.

24 Jun 2011

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.

24 Jun 2011

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Arno Therapeutics, Inc. announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with glioblastoma multiforme (GBM) who were not previously treated with Avastin and will continue toward completion.

23 Jun 2011

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today that their lead program, SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, currently in clinical trials, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).

23 Jun 2011

MAP to present LEVADEX data on migraine at 15th Congress of IHC

MAP Pharmaceuticals, Inc. today announced that LEVADEX orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011.

23 Jun 2011

Positive results from Neurelis NRL-1 Phase I pharmacokinetic study on acute repetitive seizures

In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam achieved positive clinical results in a Phase I pharmacokinetic study.

23 Jun 2011

Monash researchers receive MMV Project of the Year award for new anti-malarial drug candidate

Monash University is collaborating on the development of a potential new drug to cure malaria throughout the world.

23 Jun 2011

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd and to initiate closure of the study.

23 Jun 2011

Telaprevir drug shows promise in curing hepatitis C infection

The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection, says an international team of investigators led by Dr. Ira M. Jacobson of NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

23 Jun 2011

Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection

Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).

22 Jun 2011

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

22 Jun 2011

Drug Trial News

Nature News examines controversy surrounding Indian HPV vaccine trial

Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Oxytocin hormone holds promise for children with Prader-Willi syndrome

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

MAP to present LEVADEX data on migraine at 15th Congress of IHC

Positive results from Neurelis NRL-1 Phase I pharmacokinetic study on acute repetitive seizures

Monash researchers receive MMV Project of the Year award for new anti-malarial drug candidate

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Telaprevir drug shows promise in curing hepatitis C infection

Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Naurex commences GLYX-13 Phase II trial in treatment-resistant depression

Multiple abstracts on QNEXA long-term clinical study to be presented at ADA 2011

Endotis commences EP217609 Phase IIa study in patients undergoing open-heart surgery

Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News